Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21 GBX | -2.33% | -23.64% | +35.48% |
04-18 | Renalytix chief business officer to become president | AN |
04-18 | Renalytix Names Chief Business Officer as President | MT |
Business Summary
Number of employees: 102
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Artificial Intelligence-enabled in Vitro Diagnostics
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +26.61% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +26.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 18-03-14 |
James Sterling
DFI | Director of Finance/CFO | 54 | 18-03-14 |
Thomas McLain
PSD | President | 66 | 19-07-28 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 18-03-14 |
Michael Donovan
CTO | Chief Tech/Sci/R&D Officer | 70 | 18-03-14 |
Joseph Hutson
PRN | Corporate Officer/Principal | - | 21-07-21 |
Sales & Marketing | - | 21-06-06 | |
Salim Hamir
SEC | Corporate Secretary | - | - |
Jed Fulk
SAM | Sales & Marketing | 64 | 21-10-06 |
Howard Doran
PRN | Corporate Officer/Principal | 63 | 23-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 21-08-29 |
Chairman | 72 | 18-03-14 | |
James McCullough
FOU | Founder | 56 | 18-03-14 |
Fergus Fleming
CTO | Chief Tech/Sci/R&D Officer | 57 | 18-03-14 |
Erik Lium
BRD | Director/Board Member | 56 | 18-10-31 |
Catherine Coste
BRD | Director/Board Member | 58 | 23-06-29 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 154,368,191 | 110,735,634 ( 71.73 %) | 0 | 71.73 % |
Company contact information
Sector
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+35.48% | 41.57M | |
-15.28% | 18.56B | |
-44.98% | 2.71B | |
+17.00% | 1.85B | |
-0.51% | 1.66B | |
+25.65% | 1.22B | |
-13.90% | 989M | |
-21.76% | 896M | |
-3.53% | 745M | |
-20.73% | 660M |
- Stock Market
- Equities
- RENX Stock
- Company Renalytix Plc